Ventfort (vascular bioregulator)
Khavinson-tradition cytomedin from blood-vessel tissue, positioned as a vascular bioregulator.
At a glance
What it is: Khavinson-tradition cytomedin from blood-vessel tissue, positioned as a vascular bioregulator..
Primary research applications:
- Vascular-system support research (Khavinson framework)
- Cardiovascular-aging contexts in originating jurisdictions
Editorial summary: Ventfort is the vascular-tissue cytomedin in the Khavinson bioregulator family, paired with Vesugen (the corresponding short-peptide form). Both target the same hypothesis: tissue-specific peptide regulation of vascular function. The evidence pattern matches the rest of the family.
- Class / structure
- Cytomedin from vascular tissue
- Half-life
- Mixture-based; component-specific
- First described
- Khavinson cytomedin program
- Regulatory status
- Sold as a supplement in some jurisdictions; not FDA-approved
What is Ventfort?
Ventfort is a peptide preparation derived from young animal vascular tissue, intended to support vascular function within the Khavinson bioregulator framework.
Discovery and development
Ventfort is the vascular-tissue cytomedin in the Khavinson bioregulator framework, positioned alongside Vesugen (the corresponding short-peptide form, Lys-Glu-Asp). Both target cardiovascular and vascular function within the broader tissue-specific bioregulator concept.
Mechanism of action
The Khavinson framework proposes that vascular-tissue-derived peptide preparations carry tissue-specific regulatory information that supports endothelial and vascular smooth-muscle function. Western mechanistic validation is limited.[1]
Pharmacokinetics
Cytomedin pharmacokinetics are necessarily mixture-based. Used in oral supplement form in jurisdictions where Khavinson products are sold.
What the research shows
The peer-reviewed literature on Ventfort is summarized below across two tiers: human research (the highest standard), and preclinical / emerging research (animal models and early-stage human work).
Claims and the evidence behind them
This table summarizes commonly discussed claims and how the published evidence weighs in. The aim is clarity — supported claims, claims that look promising but need more data, and claims that outrun the science.
| Claim | What the evidence shows | Verdict |
|---|---|---|
| Supports vascular function as a Khavinson bioregulator | Originating-group framework | Uncertain |
| Has Western-grade cardiovascular-outcomes evidence | Limited | Uncertain |
Reported user experiences
How the research describes administration
Oral capsules in cyclic regimens within the Khavinson product line.
Editorial note
Administration details above describe how the peptide is given in published studies. We summarize this for educational completeness — these descriptions are not protocols, dosing recommendations, or instructions for personal use. Decisions about treatment require an appropriately licensed clinician.
Safety considerations and open questions
The takeaway
Ventfort represents the vascular-tissue arm of the Khavinson bioregulator framework. It sits in the same epistemic position as the rest of the family — interesting conceptually, real research lineage, limited Western independent validation. For cardiovascular health specifically, mainstream pharmacology and lifestyle approaches have far stronger evidence-grading.
Frequently asked questions
How does Ventfort relate to Vesugen?
Ventfort is the cytomedin (tissue extract) form; Vesugen is the corresponding synthetic short peptide (Lys-Glu-Asp). Both are vascular bioregulators in the Khavinson framework.
References
- Khavinson VK. Peptides and ageing. Neuro Endocrinol Lett. 2002;23 Suppl 3:11-144. https://pubmed.ncbi.nlm.nih.gov/12422308/
- Khavinson VK, Linkova NS. Peptide bioregulators: a new class of geroprotectors. Adv Gerontol. 2020;10:34-45. https://pubmed.ncbi.nlm.nih.gov/?term=khavinson+vascular+peptide